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pneumococcal serotypes and, 87--88

usage recommendations, 87

Pneumococci

penicillin resistance, 101

resistance, in developing countries, 91

serotypes, antimicrobial resistance and, 86, 87--88

Pneumonia

childhood mortality and, 122

*Chlamydia pneumoniae*, 10

community acquired, 15--17

diagnosis, 182--184

disease burdens in developing countries, 181--182

efficacy of pneumococcal conjugate vaccines for, 89

emerging pathogens, 185--186

etiologic agents, 182--184

incidence of pathogens, seasonal variation in, 184--185

management, 183

mortality rates, pediatric, 181--182

pneumococcal, 86

prevention, 183--184

risk factors, 185

surveillance, 188

ventilator-associated, 24, 30--31

Pneumovax®, 86--87

Poliomyelitis

deaths from, 127

eradication efforts, 208, 209

global eradication initiative, 130

surveillance, 134

Polymerase chain reaction (PCR), 256

Polymixin E (Colistin), 102

Porins, cell wall deficient mutants, 23

Poverty

childhood mortality and, 129

infectious disease emergence/reemergence and, 202--203

malaria and, 122, 169

Prebiotic, human milk as, 225

Pregnancy, intermittent preventive treatment for malaria, 177--178

Premature infant, methicillin-resistant *Staphylococcus aureus* in, 115--117

Prevention of HAIs, by antimicrobial-resistant pathogens, 32--34

Prevention of infectious disease, in travelers, 122

Prevention of mother-to-child transmission (PMTCT), 123

antiretroviral regimens for clinical trials, 191--194
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national implementation strategies, 196--197

in Southeast Asia, 190

Prevnar®. *See* Pneumococcal conjugate vaccine

Primaquine, 145

Probiotics, 234

PROTEKT Antimicrobial Surveillance Program, 95

*Pseudomonas aeruginosa*, 23, 26

Publications, focusing on antimicrobial resistance, 100

Public Health Action Plan to Combat Antimicrobial Resistance, 82

Public misconceptions, about antimicrobial agents, 96

Pulmonary abscess, neonatal, 115--117

Quinolones, 13, 249

Quinupristin/dalfopristin (Synercid®), 82

Rabies vaccines, 140, 141, 142

Rapid diagnostic tests, for malaria, 173--174
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Researchers, benefits from antimicrobial resistance concern, 100

Resistance genes, 21--22

Resource-poor countries. *See* Developing countries

Respiratory mucosa, normal flora of, 5--6

Respiratory syncytial virus (RSV), 11, 32--33

Respiratory tract infections. *See also specific types of respiratory infections*

acute, deaths from, 181

antibiotic prescriptions for, 42

antimicrobial agents for, 11--13

antimicrobial resistant, 3--4

bacterial pathogens, 6--10

diagnosis, 6

overprescribing of antibiotics for, 101

pathogens, 5, 6, 94

resistant, increased prevalence of, 5

treatment of resistant pathogens in, 6, 13--17

vaccine therapy, 17

viral, 11

Respiratory tract pathogens

*Chlamydia pneumoniae*, 10

*Mycobacterium tuberculosis*, 10

*Mycoplasma pneumoniae*, 10

*Streptococcus pyogenes*, 9--10

Rhinitis, appropriate antibiotic use for, 44

Rhinoviruses, 11

Risk factors, for healthcare associated infections, 30--31

Rotaviruses

antibodies against, in human milk, 222, 224

diarrhea and, 157

vaccine therapy, 164, 276

RSV (respiratory syncytial virus), 11, 32--33

RT-PCR, 241

Rubella vaccine, 133

*Salmonella*, antimicrobial resistant

clinical implications, 82--83

diarrhea and, 156--157, 159

to fluoroquinolones, 81--82

food animals and, 79

incidence in children, 78

multi-drug, 81

patterns of, 74, 75

serotypes, in NARMS, 74

*Salmonella krefeld*, 95

*Salmonella typhi*, 163

Salmonella vaccines, 272--273
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disease burden and, 162

infectious disease emergence/reemergence and, 202--203

pneumonia risk and, 185

Saproviruses, 238, 240--241

SARS (severe acute respiratory syndrome), 146

Schistosomiasis, 146

Secretory antibodies, in human milk, 222--223

Security, human, 200--201

Seizures, in cerebral malaria, 171, 177

Selenium deficiency, 234

SENTRY Antimicrobial Surveillance Program, 95

Serologic diagnosis, of pneumonia, 15

Severe acute respiratory syndrome (SARS), 146

Sexual practices, infectious disease emergence/reemergence and, 202

Shiga toxin-producing *E. coli*

antimicrobial resistance, 74--75

clinical manifestations, 261

diagnosis, 262--263

epidemiology, 261

immunology, 262

pathophysiology, 262

serotypes/terminology, 260

treatment, 263

vaccine therapy, 274--275

*Shigella*

antibodies against, in human milk, 222, 223, 224

antimicrobial resistance, 249--250

clinical features, 248--249

diagnosis, 249

diarrhea and, 156

global burden, 246

host responses, 247--248

pathogenicity, determinants of, 247

pathophysiology, 247

prevention, 250

resistance patterns, 73--74, 160--161

serogroups, 246

transmission, 246

treatment, 249--250

vaccine therapy, 163

*Shigella* toxin, 247

Shigella vaccines, 273

Silver nitrate eye ointment, 33

Sinusitis

antimicrobial resistant, treatment of, 15

appropriate antibiotic use for, 44

cause, determination of, 15

Sleeping sickness (African trypanosomiasis), 146

Social ecological framework, for promoting appropriate antibiotic use, 45--46

Socialized health care systems, antimicrobial resistance concerns and, 100

Society for Healthcare Epidemiology of America, 36

Socioeconomic impact, of infectious disease, 200--201

Solutions, safety assurances for, 33--34

*Staphylococcus aureus*, 10, 23, 25. *See also* Methicillin-resistant *Staphylococcus aureus*

STEC. *See* Shiga toxin-producing *E. coli*

*Streptococcus pneumoniae*

antibiotic susceptibility, 6--8, 12, 14

carriage, 41

MIC, 7--8

penicillin resistance, 6--7

prevention of resistance in healthcare facility, 32

respiratory tract infections, 6, 14--15, 16

serotypes, serial colonization with, 6

*Streptococcus pyogenes*, 9--10

*Streptococcus thermophilus*, 234

Supportive care, for malaria, 177

Surgical procedures, for neonatal lung abscess, 116--117

Surveillance, 123

data, in antibiotic therapy selection, 6

international reports, 95

pneumonia, 188

resistance rates, based on breakpoints, 107

for vaccine-preventable diseases, 134

Susceptibility testing

importance of, 105

interpretation of, 11--12

MIC breakpoints, 105--106

NCCLS criteria for, 106--107

Synercid® (quinupristin/dalfopristin), 82

Tetanus toxoid vaccine, 132

Tetracycline eye ointment, 33

Thailand

antimicrobial resistance problems, 97

costs of treating multidrug-resistant tuberculosis, 102

HIV in, 190

PMTCT interventions, 190

*Salmonella krefeld* infection, 95

trained personnel, inadequate availability of, 96

TMP-SMX. *See* Trimethoprim/sulfamethoxazole

Transfer, of antimicrobial resistance, 79, 82

Transpeptidases, 22--23

Transthoracic needle aspiration, 16

Travel, international

diarrhea prevention/management, 147

health information resources for, 139, 147--148

health risks from, 137--138

infectious disease emergence/reemergence and, 201--202

pretravel assessment for children, 138

vaccinations for, 138--142

Treatment, of antimicrobial resistance, costs of, 102

Trimethoprim/sulfamethoxazole (TMP-SMX)

resistance to, 13, 73--74

for respiratory tract infections, 13

Tuberculin skin test, 152

Tuberculosis

case management, 153

childhood incidence in U.S., 151--152

contact investigation, 153

diagnosis, 152

diagnosis in children, 152

global burden of, 150--151
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multidrug-resistant, 101, 150--151

prevention, 153
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treatment of, 152--153

Typhimurium, 81

Typhoid vaccine, 141, 142, 163, 272--273

Uganda, drug-resistant malaria in, 102
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United States, childhood tuberculosis incidence, 151--152

Urinary tract infections

antibiotic resistant bacterial pathogens, 24

epidemiology, 30--31

Vaccine-preventable diseases, routine immunizations for travelers, 138

Vaccines. *See also specific vaccines*

antidiarrheal, 163--164, 272--277
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emerging, 186--188

against malaria, 178

newer, introduction of, 133--134

for preventing HAIs, 32--33

for respiratory tract infections, 17
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Vancomycin-resistant enterococci (VRE)

emergence of, 101--102

isolation precautions, 36--37
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target-binding site alteration in, 23

treatment of, 27

Ventilator-associated pneumonia, 24, 30--31

Verotoxin-producing *E. coli. See* Shiga toxin-producing *E. coli*

*Vibrio cholerae*

antibodies against, in human milk, 222, 224

diarrhea and, 156

vaccine therapy, 163--164

Vi capsular polysaccharide vaccine, 163

Viruses. *See also specific viruses*

diarrheagenic, 157, 231

respiratory tract pathogens, 11
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deficiency, 234

supplementation, for diarrhea prevention, 163

VRE. *See* Vancomycin-resistant enterococci
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precautions, for travelers, 147
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unsafe, ingestion of, 128, 162

West Nile virus, 199, 203--204
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discontinuation of antimicrobial growth inhibitors, 78

immunization programs, 130, 131, 133
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Wound infections, antibiotic resistant bacterial pathogens, 24

Yellow fever vaccine, 139, 140, 142
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for of HIV MTCT prevention, 191--194

resistance to, 194--195
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deficiency, 234
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